Related Experiment Video
Updated: Aug 13, 2026

Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
Effects of captopril on survival in patients with heart failure
T J Newman1, C S Maskin, L G Dennick
1Division of Medical Affairs, E. R. Squibb and Sons, Inc., Princeton, New Jersey 08540.
Insights
Captopril significantly improves survival in advanced heart failure patients. A multicenter study showed a lower mortality rate in patients treated with captopril compared to placebo, highlighting its life-saving potential.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Advanced heart failure presents significant mortality challenges.
- Existing treatments have limitations in improving long-term survival.
Purpose of the Study:
- To evaluate the efficacy of captopril in improving survival rates for patients with advanced heart failure.
- To synthesize findings from multicenter studies and published literature regarding captopril's impact on mortality.
Main Methods:
- A multicenter, double-blind, placebo-controlled trial involving 105 patients with moderately severe heart failure.
- Intention-to-treat analysis of survival status over a 90-day period.
- Systematic review of six previously published comparative mortality studies.
Main Results:
- Captopril significantly reduced mortality during the 90-day study period (4% vs. 21%, p < 0.01).
- One of six reviewed studies also indicated improved survival with captopril; others were inconclusive due to low event rates.
- Potential mechanisms include favorable hemodynamic effects and neurohormonal inhibition.
Conclusions:
- Captopril demonstrates a significant survival benefit in patients with advanced heart failure.
- Further research into captopril's mechanisms of action in heart failure is warranted.
- Captopril represents a valuable therapeutic option for improving outcomes in heart failure management.
Abstract:
Results from a large multicenter study and from the published literature suggest that captopril can improve survival in patients with advanced heart failure. The survival status of 105 patients with moderately severe heart failure who participated in a multicenter, double-blind comparison of captopril and placebo therapy was ascertained on an intention-to-treat basis. During the 90-day double-blind portion of this study, 21 percent (11 of 52 patients) of placebo-assigned patients died compared with four percent (two of 53 patients) of captopril-assigned patients (p less than 0.01). In addition, six previously published studies that provided comparative mortality data were identified. In one of these, the survival rate was reported to be improved in those who received captopril; in the other five studies, no conclusion could be drawn with respect to survival since death was an infrequent event within all treatment groups. Mechanisms by which captopril may improve survival include its favorable effects on hemodynamic parameters, its association with reduced ventricular ectopic activity, and its inhibitory effects on the renin-angiotensin and sympathetic nervous systems.
More Related Videos
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
05:16Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
Related Concept Videos
Pathophysiology of Heart Failure
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure II: Pathophysiology
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure VII: Nursing Interventions